An Evaluation of the Metabolic Effects of Exenatide, Rosiglitazone, and Exenatide Plus Rosiglitazone in Subjects With Type 2 Diabetes Mellitus Treated With Metformin

Trial Profile

An Evaluation of the Metabolic Effects of Exenatide, Rosiglitazone, and Exenatide Plus Rosiglitazone in Subjects With Type 2 Diabetes Mellitus Treated With Metformin

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2014

At a glance

  • Drugs Exenatide; Rosiglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Amylin Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Jan 2010 Results have been published online in Diabetes Care.
    • 30 Sep 2009 Results presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top